ATP9A

Across TCGA pan-cancer cohorts, ATP9A Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ATP9A data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher ATP9A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ATP9A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, UCEC, and BLCA are the cancer types where ATP9A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.278	0.847	<.001	36	view →
UCEC	DFS	Median	All	0.925	0.606	.008	30	view →
BLCA	OS	Median	All	0.163	0.597	.002	15	view →
SARC	DFS	Median	All	0.109	0.611	.030	6	view →
STAD	OS	Median	IV	0.001	0.544	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ATP9A–OV (OS)

Open the OV breakdown →